Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Operational Highlights

Fourth Quarter 2024 Financial Results The company reported a net loss attributable to common stockholders of $4.1 million, or$0.27 per share, for the three months ended December 31, 2024, compared to a net loss attributable to common stockholders of $8.2 million, or$0.23 per share, for the same period in 2023. Research and development expenses were $1.8 million for the three months ended December 31, 2024, compared to$4.0 million for the comparable period in 2023, respectively. General and administrative ...